outweighs the benefits of ADHD treatment. If tics are stimulant-related, reduce the dose of methylphenidate or consider changing to Atomoxetine, or stop drug treatment. The response to medication should be assessed by the specialist at each review; patient’s and the question of whether to continue or stop medication should be addressed. Following an adequate response, drug treatment for ADHD should be continued for as long as it is clinically effective. This should be reviewed annually. For full details of the licensed indications, dosage and administration, cautions, contraindications, side effects, drug interactions and monitoring, refer to the current edition of the BNF, BNFc and SPC. Methylphenidate is a schedule 2 controlled drug; therefore all controlled drug prescription writing legislation set down in the section of and Drug ‘Controlled Drugs in the BNF applies. dependence’ References British National Formulary. No 68. BMJ Group/Royal Pharmaceutical Society of Great Britain. September 2014 March 2015. – Summary of Product Characteristics (SPC) for Concerta XL prolonged release tablets. June 2015. SPC for Equasym XL capsules. March 2014. SPC for Medikinet tablets. August 2015. SPC for Medikinet XL capsules. September 2015. SPC for Ritalin tablets. May 2015. SPC for Matoride Prolonged-release Tablets. February 2015 National Institute for Health and Clinical Excellence. Clinical Guideline 72. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. September 2008. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 12th edition. The South London and Maudsley NHS Foundation Trust, Oxleas NHS Foundation Trust. 2015. Version Control Version Date of Author/s Brief Description of Changes Approval Tim Kingscote-Davies 1.0 2015 New ESCA Dr Susan Varghese This ESCA has been approved for use by: Signature Date BCPFT Medicines Dr S Edwards Management Committee Dr Parkes Wolverhampton City CCG Prescribing Lead Sandwell & West Birmingham
outweighs the benefits of ADHD treatment. If tics are stimulant-related, reduce the dose of methylphenidate or consider changing to Atomoxetine, or stop drug treatment. The patient’s response to medication should be assessed by the specialist at each review; and the question of whether to continue or stop medication should be addressed. Following an adequate response, drug treatment for ADHD should be continued for as long as it is clinically effective. This should be reviewed annually. For full details of the licensed indications, dosage and administration, cautions, contraindications, side effects, drug interactions and monitoring, refer to the current edition of the BNF, BNFc and SPC. Methylphenidate is a schedule 2 controlled drug; therefore all controlled drug prescription writing legislation set down in the section of ‘Controlled Drugs and Drug dependence’ in the BNF applies. References British National Formulary. No 68. BMJ Group/Royal Pharmaceutical Society of Great Britain. September 2014 – March 2015. Summary of Product Characteristics (SPC) for Concerta XL prolonged release tablets. June 2015. SPC for Equasym XL capsules. March 2014. SPC for Medikinet tablets. August 2015. SPC for Medikinet XL capsules. September 2015. SPC for Ritalin tablets. May 2015. SPC for Matoride Prolonged-release Tablets. February 2015 National Institute for Health and Clinical Excellence. Clinical Guideline 72. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. September 2008. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 12th edition. The South London and Maudsley NHS Foundation Trust, Oxleas NHS Foundation Trust. 2015. Version Control Version Date of Approval Author/s Brief Description of Changes 1.0 2015 Tim Kingscote-Davies Dr Susan Varghese New ESCA This ESCA has been approved for use by: Signature Date BCPFT Medicines Management Committee Dr S Edwards Wolverhampton City CCG Prescribing Lead Dr Parkes Sandwell & West Birmingham